Retinitis Pigmentosa (RP) Market Key Players Analysis | ReGenX Biosciences, LLC, Sucampo Pharmaceuticals, Orphagen Pharmaceuticals, Inc., Inc., and Okuvision GmbH.
As of now, there are no specific treatments available for retinitis pigmentosa. Efficient treatments for retinitis pigmentosa are much awaited, particularly for genetically defined subsets of patients. Various studies suggest that this disease affects about 1 in 4,000 individuals worldwide. Without treatment, patients permanently lose central vision by the age of 60. For past many years, there have been several treatments reported, which did not completely cure the disease but were beneficial to some extent. For instance, in the past, patients used to consume a supplement of 15,000 I.U. of Vitamin A and possibly fish oil to address this conditions. In 2011, a method of treatment was patented, in which a medical dose of insulin, IGF-1, and chlorin e6 was used. Another treatment option which was proposed in November 2012 was a combined treatment regimen of oily fish (DHA), vitamin A palmitate, and lutein. This treatment was reported to slow vision loss in people suffering from the disease. Rare forms may also be treated with vitamin supplements or diet modification.
Get Brochure of the Report @ www.tmrresearch.com/sample/sample?flag=B&rep_id=91
Looking at the immense growth potential, several new players are likely to venture into the global retinitis pigmentosa market, thereby making it a highly competitive arena in the near future.
Global Retinitis Pigmentosa (RP) Market: Overview
Retinitis Pigmentosa (RP), an inherited retinal condition causing retinal degeneration and visual field loss, is a rare disease. Its initial symptoms are reduced night vision and loss of peripheral vision. It gradually causes blindness. There is no definitive cure for retinitis pigmentosa. Therefore, the market for treating this genetic disorder is vastly untapped. The available therapies apply various approaches such as stem cell therapy and transcorneal electric stimulation therapy. However, such therapies have not been approved of unanimously on account of certain intrinsic limitations.
A range of services and devices are available to aid people with vision loss to conduct their day to day activities independently. Those include anything from a vision aid and an eye care professional to orientation and mobility specialists and certified low vision therapists, among others.
Global Retinitis Pigmentosa (RP) Market: Trends and Opportunities
The global retinitis pigmentosa market has been treading a healthy growth path due to limited availability of therapeutics to cure this rare disease which has opened up a window of opportunity for new therapies and treatments. In fact, most people afflicted with the genetic disorder progress to the advanced stage of retinitis pigmentosa because of the dearth of proper cure. This has generated demand for retinal prosthesis devices for restoring the lost vision. Second Sight Medical Products, Inc., for example, offers FDA approved Argus II retinal prosthesis system meant for patients with advanced retinitis pigmentosa. This device does the function of degenerated retinal cells and enhances the patient’s ability to see images and movement.
A new approach known as optogenetics, which involves applying gene therapy for restoring vision, is currently being researched upon by companies operating in the ophthalmology market. It helps to power cells, especially ganglion cells, to respond to light after the degeneration of rod cells and cone cells. Further, the orphan drug designation given by the FDA and European Commission to ReN003 by ReNeuron in the U.S. and Europe in 2013 is another positive development in the market. ReN003 is a retinal stem cell therapy candidate.
Global Retinitis Pigmentosa (RP) Market: Regional Outlook
Based on geography, the global retinitis pigmentosa market can be segmented into North America, Europe, Asia Pacific, and the Rest of the World. Among them, North America and Europe dominate the market powered by the developed markets of the U.S and U.K. where exhaustive research and development activities have been carried out in this direction. However, the Asia Pacific retinitis pigmentosa market is also poised for growth due to the large patient pool in the region, who need to be treated for retinitis pigmentosa. The Rest of the World also has a substantial number of people suffering from this rare genetic disorder.
Get TOC for Detailed Facts and Numbers @ www.tmrresearch.com/sample/sample?flag=T&rep_id=91
Companies Mentioned in Report
To present an study the current competitive dynamics in the global retinitis pigmentosa market, the report has profiled some of the major players involved in the development and commercialization of products in the field such as ReNeuron Group plc, Amarantus BioScience Holdings, Inc., Ocugen, Inc., ReGenX Biosciences, LLC, Sucampo Pharmaceuticals, Orphagen Pharmaceuticals, Inc., Inc., and Okuvision GmbH.
Highlights of the report:
A detailed analysis of key segments of the market
Recent developments in the market’s competitive landscape
Detailed analysis of market segments up to second or third level of segmentation
Historical, current, and projected future valuation of the market in terms of revenue and/or volume
Key business strategies adopted by influential market vendors
Outline of the regulatory framework surrounding and governing numerous aspects of the market
Growth opportunities in emerging and established markets
Recommendations to market players to stay ahead of the competition
TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.
Head Internet Marketing
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Retinitis Pigmentosa (RP) Market Key Players Analysis | ReGenX Biosciences, LLC, Sucampo Pharmaceuticals, Orphagen Pharmaceuticals, Inc., Inc., and Okuvision GmbH. here
News-ID: 1678155 • Views: 300
More Releases from TMR Research
Weigh in Motion Market Share and Growth Factors Impact Analysis 2018 – 2028
Weigh in Motion Market – Introduction Weigh in motion (WIM) devices are specifically designed equipment to record the truck axle & gross vehicle weights as they drive over a measuring site or a sensor. The existing weigh in motion systems are witnessing an increasing traction over the conventional static weigh stations, as they don’t require the vehicle to stop, which make them a more efficient option. Numerous benefits of weigh
Gas Analysis Systems Market Competitive Landscape Analysis with Forecast by 2028
Gas Analysis Systems Market Introduction Gas analysis systems are used to monitor or analyze various chemical gases present in the product or sample. It helps in identifying the gas and also provides information on the quantity, displaying in the numerical or graphical form. The standard gas analysis system includes sample probe, line, filter, gas conditioning system including pump, cooler, and calibration gas system, and series of gas analyzers. Industries across sectors
VRF System Market - Product Application 2028 | Commercial Residential Others (Me …
VRF System Market – Introduction Variable refrigerant flow (VRF) system is widely adopted to control the amount of refrigerant flowing to various evaporators with different configurations and capacities. This growing adoption of VRF systems is attributed to their ability to provide comfort without swings at room temperature by offering the desired supply of heating or cooling when the need arises. VRF system caters to various applications owing to its availability
Digital Out of Home Market Dynamic Business Environment during 2018 - 2028
Digital Out of Home Market– Introduction Digital out of home (DOOH), also referred to as digital signage is a modern form of advertising that has effectively replaced traditional forms of advertising and marketing. Digital out of home advertising enables local vendors and advertisers to engage customers in real time, and track and monitor the effectiveness of their marketing messages. DOOH is a rapidly growing and dynamically-served visual mode of advertising
More Releases for Retinitis Pharmaceuticals Pigmentosa
Retinitis Pigmentosa (RP) Market : Sucampo Pharmaceuticals, Orphagen Pharmaceuti …
Global Retinitis Pigmentosa (RP) Market: Snapshot Retinitis pigmentosa, in which patients usually lose night vision in teenage years, side vision in middle age, and central vision in later life because of steady loss of cone photoreceptor cells and rod. Measures of retinal function, such as the electroretinogram, indicate that photoreceptor function is reduced usually several years before visual-field scotomas, symptomic night blindness, or reduced visual acuity arise. As of now, there
Retinitis Pigmentosa (RP) Market 2017-2025 : Sucampo Pharmaceuticals, Orphagen P …
Global RFID in Pharmaceuticals Market: Snapshot The U.S. Food and Drug Administration (FDA) has played a vital role in escalating the widespread adoption of Radio Frequency Identification (RFID) in the pharmaceutical sector to strengthen anti-counterfeiting and track-and-trace efforts. Besides these benefits, RFID technology is acknowledged for its ability to increase supply chain efficiency, reduce errors by proper storage of information, boost patient safety and monitoring, enhance staff, patient, and asset
Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2017
Market Research Hub includes new market research report "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2017" to its huge collection of research reports. Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance and x-linked inheritance. Request Free